-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Mutation analysis of circadian clock gene BMAL1 in 21 Pakistani congenital cataract families
Udita Bagchi, Shazia Micheal, Sorath Noorani Siddiqui, Muhammad Imran Khan, Jacoline B Ten Brink, MariePaule Felder-Schmittbuhl and Arthur A Bergen
Short Communication: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Pan-Asian clinical research coordination: challenges and opportunities
Karen Wai Kar Luen, Ken J Lee
Editorial: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Data fraud in clinical trials
Stephen L George, & Marc Buyse
Clinical Trail Perspective: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Allopurinol-thiopurine combination therapy in inflammatory bowel disease
Margien L Seinen, Nanne KH de Boer, Adriaan A van Bodegraven, Stephen B Hanauer & Frank Hoentjen
Special Report: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation